Risperdal Plaintiffs Push For Release Of J&J Studies

Law360, Philadelphia (December 11, 2013, 2:19 PM EST) -- Plaintiffs in a cluster of product liability lawsuits against a Johnson & Johnson unit over the antipsychotic drug Risperdal told a Pennsylvania judge on Tuesday that documents detailing the medication’s risks were too vital to the public interest to remain under seal as part of court proceedings.

In a brief, attorneys representing plaintiffs in nearly 275 product liability suits against Janssen Pharmaceuticals Inc. pending in the Philadelphia County Court of Common Pleas blasted a motion by the drugmaker looking to maintain a 2011 order protecting the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.